Yahoo
NasdaqGS - Delayed Quote USD

10x Genomics, Inc. (TXG)

62.65 -0.57 (-0.90%)
At close: September 4 at 4:00:00 PM EDT
62.39 -0.26 (-0.42%)
After hours: September 4 at 7:30:03 PM EDT
Trade TXG on Coinbase
Chart Range Bar
Loading chart for TXG
  • Previous Close 63.22
  • Open 62.73
  • Bid 44.47 x 200
  • Ask 65.00 x 100
  • Day's Range 60.99 - 63.48
  • 52 Week Range 11.16 - 66.94
  • Volume 1,469,471
  • Avg. Volume 3,135,901
  • Market Cap (intraday) 8.163B
  • Beta (5Y Monthly) 2.08
  • PE Ratio (TTM) --
  • EPS (TTM) -0.60
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 51.00

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

www.10xgenomics.com

1,178

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TXG
284.12%
S&P 500 (^GSPC)
12.75%

1-Year Return

TXG
361.68%
S&P 500 (^GSPC)
18.71%

3-Year Return

TXG
15.91%
S&P 500 (^GSPC)
70.93%

5-Year Return

TXG
66.17%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 151.04M
Earnings -17.93M
Profit Margin -11.87%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
-18.0%
-16.0%
-14.0%
-12.0%
-10.0%

Analyst Insights

View More

Analyst Price Targets

40.00 Low
51.00 Average
62.65 Current
70.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/1/2026
Analyst RBC Capital
Rating Action Initiated
Rating Sector Perform
Price Action Announces
Price Target 70

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.18%

  • Return on Assets (ttm)

    -5.05%

  • Return on Equity (ttm)

    -9.40%

  • Revenue (ttm)

    616.91M

  • Net Income Avi to Common (ttm)

    -75.12M

  • Diluted EPS (ttm)

    -0.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    552.03M

  • Total Debt/Equity (mrq)

    9.54%

  • Levered Free Cash Flow (ttm)

    179.66M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: